This finding might indicate that blood MALT1 might predominantly predict treatment response to systemic biologic therapy, while its ability to predict treatment response to other therapies was relatively weak in psoriasis patients, and the predictive ability of blood MALT1 for whole treatment response was mainly derived from the former. The gene discussed is MALT1; the disease is psoriasis.